The age groups more affected by SARS-CoV-2 in children and the role of schools in the COVID-19 pandemic in Israel - January 2020-March 2021 The age groups more affected by SARS-CoV-2 in children

Article Sidebar

PDF Download
Published Mar 31, 2022
DOI: https://doi.org/10.18103/mra.v10i3.2706

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Ravit Bassal
Israel Center for Disease Control, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel ; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Victoria Indenbaum
Central Virology Laboratory, Israel Ministry of Health, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Ella Mendelson
Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel ; Central Virology Laboratory, Israel Ministry of Health, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Yaniv Lustig
Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel ; Central Virology Laboratory, Israel Ministry of Health, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Lital Keinan-Boker
Israel Center for Disease Control, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel ; School of Public Health, University of Haifa, Haifa, Israel

Abstract

We analyzed data from a serological study performed on 2,765 samples from the Israeli National Sera Bank (INSB), established in 1997 in the Israel Center for Disease Control (ICDC) collected from children aged 0-<16 years during January 2020-March 2021. Trends in seropositivity rates to SARS-CoV-2 were evaluated using Joinpoint within specific age groups and compared to educational institutions activity. Seropositivity rates increased significantly in the 0-<6 and 12-<16 years age groups and were parallel in the 0-<6 years age group and partially parallel in the 12-<16 years to educational institutions activities. Non-significant increase in seropositivity rates were observed in the age groups 6-<10 and 10-<12 years. Apparently, exposure to SARS-CoV-2 in children was driven not only by educational activities but also by other factors.

Keywords: SARS-CoV-2, Children, Schools, Pandemic, Seroprevalence, Trend

Article Details

How to Cite
BASSAL, Ravit et al. The age groups more affected by SARS-CoV-2 in children and the role of schools in the COVID-19 pandemic in Israel - January 2020-March 2021. Medical Research Archives, [S.l.], v. 10, n. 3, mar. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2706>. Date accessed: 23 nov. 2024. doi: https://doi.org/10.18103/mra.v10i3.2706.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 10 No 3 (2022): Vol.10 Issue 3 March 2022
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. World Health Organization Coronavirus disease (COVID-19) situation reports [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2. COVID-19 Coronavirus Pandemic [Available from: https://www.worldometers.info/coronavirus/.
3. Coronavirius in Israel [Available from: https://datadashboard.health.gov.il/COVID-19/general.
4. Ulyte A, Radtke T, Abela IA, Haile SR, Berger C, Huber M, et al. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. Bmj. 2021;372:n616.
5. Szépfalusi Z, Schmidthaler K, Sieber J, Kopanja S, Götzinger F, Schoof A, et al. Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: A cross-sectional study. Pediatr Allergy Immunol. 2021;32(4):762-70.
6. Smith BK, Janowski AB, Danis JE, Harvey IB, Zhao H, Dai YN, et al. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA. mSphere. 2021;6(1).
7. Reicher S, Ratzon R, Ben-Sahar S, Hermoni-Alon S, Mossinson D, Shenhar Y, et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol. 2021:1-8.
8. Indenbaum V, Lustig Y, Mendelson E, Hershkovitz Y, Glatman-Freedman A, Keinan-Boker L, et al. Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021;26(48).
9. Bassal R, Cohen D, Green MS, Keinan-Boker L. The Israel National Sera Bank: Methods, Representativeness, and Challenges. International Journal of Environmental Research and Public Health. 2021;18(5):2280.
10. Indenbaum V, Koren R, Katz-Likvornik S, Yitzchaki M, Halpern O, Regev-Yochay G, et al. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS One. 2020;15(11):e0241164.
11. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020;29:100651.
12. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999-1009.
13. Smith BK, Janowski AB, Fremont AC, Adams LJ, Dai YN, Farnsworth CW, et al. Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021. mSphere. 2021;6(4):e0045021.
14. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. Eur J Epidemiol. 2021;36(7):715-25.
15. Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(21).
16. Fukumoto K, McClean CT, Nakagawa K. No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020. Nat Med. 2021.
17. Barcellini L, Forlanini F, Sangiorgio A, Gambacorta G, Alberti L, Meta A, et al. Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan? PLoS One. 2021;16(9):e0257046.